- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.04. | GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn | ||
| 07.04. | AstraZeneca's Imfinzi regimen receives EC approval to treat resectable NSCLC | ||
| 07.04. | J&J's Stelara granted EC approval to treat Crohn's disease in paediatric patients | ||
| 07.04. | The AI advantage: seven steps to augmented pharma brand planning | ||
| 04.04. | Amgen's Uplizna approved by FDA as first treatment for rare disease IgG4-RD | ||
| 04.04. | AstraZeneca/Daiichi Sankyo's Enhertu receives EC approval for HER2-low breast cancer | ||
| 04.04. | Novartis' Vanrafia granted FDA approval for rare kidney disease IgA nephropathy | ||
| 04.04. | The importance of the human touch in today's AI world | ||
| 03.04. | Genmab announces EC approval of Tivdak in recurrent or metastatic cervical cancer | ||
| 03.04. | Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma | ||
| 03.04. | Pfizer and Flagship Pioneering enter autoimmune disease partnership | ||
| 03.04. | Life sciences in Europe - the top 20 global cities | ||
| 02.04. | BMS receives positive CHMP opinion for perioperative Opdivo regimen in lung cancer | ||
| 02.04. | BeiGene's Tevimbra recommended by CHMP to treat small cell lung cancer | ||
| 02.04. | Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11 | ||
| 02.04. | ALS - innovative developments and investigational treatments | ||
| 01.04. | AstraZeneca's Imfinzi regimen approved by FDA to treat bladder cancer | ||
| 01.04. | Novartis' Pluvicto granted FDA approval for expanded prostate cancer use | ||
| 01.04. | Pfizer's RSV vaccine receives EC approval for individuals aged 18 to 59 years | ||
| 01.04. | OPEN Health appoints Matt D'Auria as CEO | ||
| 01.04. | Is critical thinking at risk? | ||
| 31.03. | Sanofi's Qfitlia granted FDA approval to treat haemophilia A or B | ||
| 31.03. | Johnson & Johnson's Tremfya recommended by CHMP to treat Crohn's disease | ||
| 31.03. | FDA approves Exelixis' Cabometyx to treat advanced neuroendocrine tumours | ||
| 31.03. | Brand building: pharma's billion dollar blind spot |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
